Last reviewed · How we verify
NCT05607667
Clinical Trial in China for Aortic Valve Stenosis
NA trial testing Transcatheter aortic valve replacement in Diseases of Aortic Valve in 15 participants. Completed in 3 July 2024.
3 July 2024
Quick facts
| Lead sponsor | Genesis Medtech Corporation |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 14 October 2022 |
| Primary completion | 3 July 2024 |
| Estimated completion | 3 July 2024 |
| Sites | 15 locations across China |
Drugs / interventions tested
- Transcatheter aortic valve replacement
Conditions studied
- Diseases of Aortic Valve — all drugs for Diseases of Aortic Valve →
- Aortic Stenosis Disease — all drugs for Aortic Stenosis Disease →
Sponsor
Genesis Medtech Corporation
Who can join
65 and older, any sex, with Diseases of Aortic Valve or Aortic Stenosis Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this clinical study is to evaluate the effectiveness and safety of the transcatheter aortic valve system in the treatment of patients with severe aortic stenosis disease who are at high or prohibitive surgical risk.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05607667
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Transcatheter aortic valve replacement
Trials testing the same drug.
- NCT07532317 — A Prospective, Multinational, Multicentre, Open-label, Randomized Trial to Evaluatesafety and Effectiveness of Meril's M · NA · not yet recruiting
- NCT06924151 — Isolated Surgical Aortic Valve Replacement in Low Risk AS Patients · NA · recruiting
- NCT06743568 — Efficacy of Self-expandable and Balloon-expandable Valves in Patients With Ascending Aortic Dilation · NA · recruiting
- NCT06589063 — Transcatheter Aortic Valve Replacement in Severe Low Flow, Low Gradient Aortic Stenosis · recruiting
- NCT06257043 — Safety and Efficacy of Post-marketing Transcatheter Aortic Valves in "Real World" Chinese Patients · recruiting
Other Genesis Medtech Corporation trials
Trials by the same sponsor.
- NCT05580952 — Clinical Trial in China · NA · unknown
- NCT05434676 — SOLUTION Trial in China · NA · unknown
- NCT05433376 — SOLSTICE Trial in China · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05607667 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Genesis Medtech Corporation
- Last refreshed: 28 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05607667.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing